Brief: Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals For Sotagliflozin In All Markets Outside Of The U.S. And Europe
16/10/2024 21:37
Oct 16 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O :
* VIATRIS ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH
LEXICON
PHARMACEUTICALS FOR SOTAGLIFLOZIN IN ALL MARKETS OUTSIDE OF THE
U.S. AND EUROPE
* VIATRIS INC - ENTERS EXCLUSIVE LICENSING AGREEMENT WITH
LEXICON
FOR SOTAGLIFLOZIN
* VIATRIS INC - TO PAY $25 MILLION UPFRONT FOR SOTAGLIFLOZIN
RIGHTS
Source text for Eikon: ID:nPn4lFzpxa
Further company coverage: LXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview